Trimebutine

Trimebutine

Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.[1] The maleic acid salt of trimebutine is marketed under the trademark of Debridat, Recutin, Polybutin,[2] or Modulon for treatment of irritable bowel syndrome and other gastrointestinal disorders. The major product from drug metabolism of trimebutine in human beings is nor-trimebutine,[3] which comes from removal of one of the methyl groups attached to nitrogen. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract.[4] Both Trimebutine and its metabolite are commercially available.

See also

References